MicroRNA (miRNA), noncoding segments of RNA involved in post-transcriptional regulation of protein expression are differentially expressed in eutopic endometrium of women with and without endometriosis compared to endometriotic lesions. However, endometriotic lesion types are known to be biochemically distinct and therefore hypothesized that miRNAs are differentially expressed in endometriomas compared to peritoneal and deep-infiltrating lesions. Therefore, endometrial biopsies and ectopic implants from women (n = 38) undergoing laparoscopic surgery for chronic pelvic pain were collected. Samples of endometriomas, peritoneal or deep-infiltrating lesions were selected from our tissue bank for study participants who exclusively had only one lesion type noted on their surgical report. Quantitative real-time polymerase chain reaction for miR-9, miR-21, miR-424, miR-10a, miR-10b, and miR-204 was performed. miR-204 expression was significantly lower (P = 0.0016) in the eutopic endometrium of women with endometriosis compared to controls. Relative expression of miR-21, miR-424, and miR-10b differed significantly (P < 0.05) across endometriotic lesion types. Finally, all miRNAs isolated from endometriomas, peritoneal and deep-infiltrating lesions studied were differentially expressed compared to matched eutopic endometrium samples. We therefore conclude that miRNA expression in the eutopic endometrium from women with endometriosis differs from symptomatic controls. Moreover, miRNA expression pattern is dependent on the endometriotic lesion type studied. We suggest that identification of different miRNA expression patterns for endometriomas, peritoneal and deep-infiltrating lesions could contribute to individualized patient care for women with endometriosis.
Introduction
Endometriosis is an estrogen-dependent gynecological disorder affecting approximately 10% of women during the reproductive lifespan [1] . Hallmarks of endometriosis include chronic pelvic pain and infertility, both of which negatively impact the quality of life in affected women, leading to significant morbidity and health care costs [2] [3] [4] [5] . Diagnostic delays are common and average approximately 6.7 years before a definitive diagnosis is achieved [6] . Although retrograde menstruation is a widely accepted explanation for the development of endometriosis [7] , the common occurrence of retrograde menstruation in 90% of the general female population, most of whom do not develop endometriosis [7, 8] , suggests that alternative mechanisms are involved [9] [10] [11] . Dysregulation of multiple signaling pathways including cell adhesion, tissue remodeling, cell death, inflammation, immune suppression, angiogenesis, proliferation, and neurogenesis have all been documented in women with endometriosis compared to controls [12] . Individual markers in the serum, plasma, peritoneal (PE) fluid, urine, and endometrial tissue have all been investigated as potential diagnostic tools [13] [14] [15] [16] , but sensitivity and specificity has remained suboptimal [13, [17] [18] [19] [20] . Consequently, the search for novel individual or panels of makers remains a high-priority research objective [21] .
Epigenetics studies revealed differences in the expression of DNA methyltransferases [22] and hypomethylation of progesterone receptor B [23] . These encouraging results highlight the importance of epigenetic regulation in the pathophysiology of endometriosis and identification of novel therapeutic targets [24] . Recently, expression profiling of microRNAs (miRNA), small noncoding RNA molecules of approximately 20 nucleotides in length, revealed differential expression in women with endometriosis vs. controls [25] [26] [27] [28] . MicroRNAs function to alter gene expression post-transcriptionally by degradation of the target mRNA transcript or via translational suppression [29] . MicroRNA has the ability to regulate hundreds of mRNAs and therefore has a considerable effect on gene expression networks [30] . Greater than 2000 mature human miRNA sequences have been identified and are thought to regulate approximately 50% of all protein coding genes. Several recent studies have also documented aberrant expression of different miRNA targets in the eutopic and ectopic endometrium of women with endometriosis [25, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Abnormal miRNA expression has already been attributed to benign gynecological conditions, gynecological malignancies, and fertility disorders in women [41] . They are stable in biological fluids, and are highly expressed and conserved among species [42] . Consequently, circulating concentrations of miRNA have also been explored as potential diagnostic markers of endometriosis [38, [42] [43] [44] [45] [46] [47] . Although encouraging results have been documented using a panel of miRNA [47] as potential diagnostic markers of endometriosis, several issues remain to be resolved. Specifically, reproducibility of results across studies has not been achieved potentially owing to differences in target miRNAs chosen, definitions of controls, and heterogeneity of endometriosis.
While differential expression of miRNA in the endometrium compared to endometriotic tissue has been documented, few studies have compared miRNA expression patterns in different endometriotic lesions [25, 28, 31, 36, 48] . However, reproducibility of study results has not been addressed previously. Moreover, biochemical differences among endometriotic lesions collected from different anatomical sites has previously been suggested [49] . Therefore, the objective of the current study is to determine differences in miRNA expression between eutopic endometrium of women with and without endometriosis (Controls), and between different types of endometriotic implants including ovarian endometriomas (OMA), PE lesions, and deep-infiltrating endometriosis (DIE). Three miRNAs, miR-9, miR-21, and miR-424, were selected for study because their expression has been documented in prior endometriosis studies [25, 31, 36, 50, 51] . In addition, significantly higher circulating concentrations of brain-derived neurotrophic factor (BDNF) were reported in women with endometriosis compared to controls [52] [53] [54] . Moreover, inhibition of miR-10b increased BDNF expression and cell proliferation in goat granulosa cells [55] . In another study [56] , inhibition of miR-204 increased BDNF mRNA expression, resistance to apoptosis, and invasiveness and metastatic behavior in epithelial ovarian cancer cells. Therefore, we also chose three additional miRNAs, miR-10a, miR-10b, and miR-204, which have been shown to regulate BDNF expression in the ovary [55] [56] [57] [58] .
Materials and methods

Study participant recruitment
Women with chronic pelvic pain scheduled for laparoscopic surgery at McMaster University Medical Centre between April 2011 and March 2017 were recruited and screened for inclusion in this study. Exclusion criteria included the following: individuals unable to provide consent, age < 18 years, women diagnosed with adenomyosis, greater than a pack/day smoker, and use of gonadotropin-releasing hormone agonist (GnRH-a) 3 months prior to surgery. Oral contraceptive use was variably reported at different time points by most study participants before surgery but use ceased before laparoscopy. All study participants underwent gynecological laparoscopic surgery for pelvic pain thought to be due to endometriosis. Thirty-eight women had endometriosis confirmed by histology with lesions that were either exclusively OMA, PE, or DIE lesions. Endometriosis was excluded by laparoscopic surgery in nine women with chronic pelvic pain who were included as symptomatic controls.
All participants completed questionnaires on demographics and gynecologic variables. Questions included average length of menstrual cycle, age of first menstruation, pain scale of pelvic pain, and medical histories. The stage of endometriosis was determined by the surgeon (NAL) during surgery according to the revised Classification of the American Society of Reproductive Medicine (rASRM) [59] . This study was approved by the Research Ethics Board, McMaster University (REB 12-083-T), and all participants provided written informed consent before surgery.
Sample preparation
Quantitative polymerase chain reaction Endometrial samples were obtained by pipelle biopsy during surgery from study participants (n = 38) and control subjects (n = 9). The samples stabilized with RNAlater (Thermo Scientific, Mississauga, ON) and frozen until required for RNA analysis.
Samples were weighed (30 mg) and placed into 700 μl of QIAzol Lysis Reagent (Qiagen, Toronto, ON) before homogenization (Bio-Gen, Oxford, CT). Total miRNA was isolated from the samples with the miRNeasy mini kit (Qiagen) according to manufacturer's instructions; wash steps were performed twice to ensure removal of potential inhibitors in the final eluate. MicroRNA concentrations and purities were measured with the NanoDrop 2000 (Thermo Scientific). Synthesis of cDNA was performed on the miRNA fraction with miScript II RT Kit (Qiagen) for miRNA, as per manufacturer's instructions. Complementary DNA synthesis reactions were performed in an iCycler Thermocycler (Bio-Rad, Mississauga, ON). The samples were later diluted with RNase-free water to a final concentration of 3 ng/μl. The expression levels of miR-9, miR-21, miR-424, miR-10a, miR-10b, and miR-204 were measured using quantitative real-time polymerase chain reaction (qPCR) with the use of miScript SYBR Green PCR kit (Qiagen). Reference genes SNORD95, SNORD96A, and SNORD68 were used to normalize the data. Primers were all miScript Primer Assays purchased form Qiagen, except for miR-204, which is a MystiCq microRNA qPCR assay primer (Sigma, Oakville, ON). Real-time PCR was performed using the LightCycler480 machine (Roche, Laval, QC) in 384-well plates with 10 μl in each reaction mixture. Reactions were subject to an initial activation step of 95˚C for 15 min, followed by 45 cycles of 94˚C for 15 s, 55˚C for 30 s, and 70˚C for 30 s. Each sample was run in triplicate for analysis.
Statistical analysis
Demographic variables, such as ethnicity, and menstrual cycle stage are reported as frequency and percentage, except for age which was calculated as mean (±SD). Differences between cases and controls were measured with Mann-Whitney U-test, Fisher exact tests, or Chi-Squared analysis. Relative quantification of miRNAs was performed using SNORD95, SNORD96A, and SNORD68 as references genes in OMA samples (n = 15), and PE samples (n = 11) and DIE samples (n = 13) using the LightCycler480 (Roche) software. The individual ratio for each sample was divided by the average control sample ratio following the 2 − Ct method to detect fold change of expression [60] .
The Kolmogorov-Smirnov test for normality was used to determine if the data were normally distributed using GraphPad Prism version 5.01 (La Jolla, CA). A Student t-test or Mann-Whitney Utest was performed to compare miRNA expression between eutopic endometrium of cases and controls, and between ectopic lesion and matched eutopic endometrium for women with endometriosis. A one-way ANOVA or Kruskal-Wallis Analysis of Ranks was performed on miRNA expression between the ectopic implants, and between the eutopic endometrium of controls and cases, separated by lesion type. Post hoc analysis was performed using a Tukey test or a Dunn test. Linear regression was performed on ectopic implants to test for a significant trend. Data are presented in scatter-plot graphs depicting medians. Comparisons with a P ≤ 0.05 were considered statistically significant.
Results
Demographic variables
The mean age of controls and cases were 34.7 ± 8.0 and 33.9 ± 4.3 years, respectively, and demographic variables did not differ significantly between cases and controls (Table 1) . Most cases were classified as moderate to severe cases (rASRM stage III-IV). Menstrual cycle stage (P = 0.884) and ethnicity (0.288) did not differ between cases and controls. miRNA expression Control endometrium vs. eutopic endometrium MicroRNA expression was compared between control eutopic endometrium (n = 9) and eutopic endometrium of women with endometriosis (n = 38). miR-204 expression was significantly (P = 0.016) downregulated in the eutopic endometrium of women with endometriosis compared to symptomatic controls (Figure 1 ), while there was no difference in miR-21, miR-424, and miR-10b (Figure 1 ), miR-9, and miR-10a expression (Figure 2 ).
MicroRNA expression between ectopic implants
Of the six miRNAs quantified, expression of miR-21, miR-424, and miR-10b was differentially regulated between endometriotic lesions from different anatomical sites. miR-21 expression was significantly lower in PE compared to OMA (P = 0.004; Figure 1) , and a similar pattern of expression was observed for miR-424, with significant downregulation in PE compared to OMA (P = 0.011; Figure 1) . miR-10b expression in DIE lesions was significantly lower than OMA (P = 0.037; Figure 1 ). While miR-10a was not differentially expressed between lesions from different anatomical sites ) and control endometrium (n = 9) (left) and between ectopic implants OMA (n = 15), PE (n = 11), DIE (n = 10) (right). * P < 0.05, * * P < 0.01.
(P = 0.122), linear regression analysis suggested a significant trend towards increased expression in OMA vs. PE and DIE (P = 0.049; Figure 2 ). Finally, there was no relationship between the expression of miR-9 (P = 0.146) or miR-204 (P = 0.131) with lesion type; however, linear regression analysis suggests a trend towards an association between miR-9 expression and location of ectopic implant (P = 0.055, Figure 2 ).
Eutopic endometrium from cases with different lesion types vs. control endometrium
MicroRNA expression varied significantly between lesions from different anatomical sites suggesting that potential biochemical differences in lesions. We therefore compared miRNA expression between the eutopic endometrium of women with specific lesion types to the eutopic endometrium of controls. Expression of miR-424 was significantly lower in the eutopic endometrium of women with PE (n = 11), compared to control endometrium (P = 0.024; Figure 3 ). The eutopic endometrium of women with both OMA (n = 15) and DIE (n = 13) demonstrated lowered expression of miR-204 compared to controls with P = 0.034, and P = 0.027, respectively ( Figure 3) . Finally, miR-10a and miR-10b demonstrated a similar pattern of expression in the eutopic endometrium of women with DIE compared to controls. Specifically, we observed downregulation of miR-10a (P = 0.028) and miR-10b (P = 0.005) in the eutopic endometrium of women with DIE compared to controls (Figure 3 ).
Ectopic lesion vs. matched eutopic endometrium
MicroRNA expression in ectopic implants was compared against expression in matched eutopic endometrium (within the same woman). Expression of the following miRNAs was significantly lower compared to the matched eutopic endometrium. In women with PE, miR-9 (P = 0.028), miR-21 (P = 0.018), and miR-424 (P = 0.011) were significantly downregulated in the endometriotic tissue (PE) compared to the matched eutopic endometrium (Figure 4 ). In women with DIE, the expression of miR-21 (P = 0.031) and miR-424 (P = 0.025) was significantly lower in ectopic implants (DIE) compared to matched eutopic endometrium. Although not significant, there was a trend towards lower miR-204 expression (P = 0.051; Figure 4 ). Finally, miR-10a expression was significantly lower (P = 0.016) in women with OMA compared to eutopic endometrium of the same women ( Figure 4) . No change in miR-10b was noted when comparing each implant to its matched eutopic endometrium ( Figure 4 ).
Discussion
Results of the present study demonstrated downregulation of miR-204 expression in the eutopic endometrium of women with endometriosis compared to symptomatic controls. However, our results revealed significant differences in the expression of all miR's studied (miR-9, -10a, -10b, -21, -204, and -424) after comparing Figure 2 . The expression of (A) miR-9 between eutopic case (n = 35) and control endometrium (n = 9) (left) and between ectopic implants OMA (n = 15), PE (n = 11), DIE (n = 10), with linear regression depicting the relationship of miR-9 and endometriotic implants. Expression of (B) miR-10a, and accompanying linear regression analysis between endometriotic implant. Significance denoted P < 0.05.
eutopic endometrium from women with exclusively OMAs, PE, or DIE lesions with symptomatic controls. Moreover, miRNA expression also differed between the types of endometriotic lesions, from different anatomical sites. In the current study, miR-424 was differentially expressed in OMAs vs. PE sites, in the eutopic endometrium of women with PE and control endometrium, and between eutopic and ectopic sites of women with PE and DIE. Our results contrast with those of a previous study [31] . Specifically, miR-424 expression was higher in the eutopic endometrium from women without endometriosis compared to women with endometriosis [31] . Furthermore, expression of miR-424 was significantly upregulated in OMAs compared to eutopic case endometrium, and upregulated in PE and DIE compared to both eutopic case endometrium and control endometrium [31] , whereas we found no differences in miR-424 expression in the eutopic endometrium of women with endometriosis vs. symptomatic controls. While increased expression of miR-424 in OMAs vs. PE lesions in the present study agrees with those of this prior study, we suggest that divergent results may be explained by differences in the definition of control groups used. In the current study, women in the control group were undergoing a laparoscopy for pelvic pain, whereas in the prior study [31] the control group consisted of asymptomatic women. In endometrial tissue of women with endometriosis, miR-424 inversely regulated vascular endothelial growth factor (VEGF) expression [31] . Furthermore, miR-424 was found to target VEGF and basic fibroblast growth factor via VEGF receptor 2 and fibroblast growth factor receptor 1, respectively, in endothelial cells, reducing cell proliferation and migration in vitro [50] . In endometrial cancer cells, overexpression of miR-424 suppressed 17β-estradiol-induced cell proliferation by targeting the PI3K/AKT signaling pathway mediated by G-protein coupled receptor [61] . We therefore speculate that the lower expression of miR-424 in ectopic tissues of the current study could contribute to overexpression of VEGF and increased estradiol-induced cell proliferation within endometriotic lesions ( Figure 5 ).
Similar to the pattern of miR-424 expression, results of the present study revealed increased miR-21 expression in OMAs compared to PE, and we observed increased expression in eutopic endometrium of women with PE and DIE, compared to the respective lesion type. No changes in the eutopic endometrium of cases with any lesion type, compared to controls, were observed. Our results do not match those of a prior study [36] , where they saw increased miR-21 expression in OMAs compared to eutopic endometrium of cases, and elevated expression in OMAs and DIE compared to control endometrium, and no changes observed in PE. We suggest that divergent findings can be explained by differences in comparisons made and the burden of disease in study participants. Specifically, in the present study, comparisons between ectopic lesions and eutopic Figure 3 . Relative expression of (A) miR-9, (B) miR-21, (C) miR-424, (D) miR-204, (E) miR-10a, and (F) miR-10b between control endometrium (n = 9) and eutopic endometrium of women with one of three lesion types, OMA (n = 13), PE (n = 10), and DIE (n = 12). * P < 0.05, * * P < 0.01.
Control
endometrium of controls were not made. We are unsure of the biological relevance of comparisons between ectopic lesions in women with endometriosis and eutopic endometrium of women without endometriosis. In the present study, we limited comparisons to eutopic endometrium and ectopic lesions within cases, assuming that differential expression of the miRNAs within the women affected would reflect disease processes as opposed to individual differences in gene expression and regulation. In the current study, we were careful to choose specimens from our tissue bank from women with solely one lesion type (except one case) to avoid potential influences of disease burden on miRNA expression. In the previous study [36] , the DIE and PE groups were subsets of the OMA group, containing women with 2 or more lesion types. Although miR-21 expression has been documented in women with endometriosis [36, 62] , its role in endometriosis is unknown. Overexpression of miR-21 has been identified in a number of cancers, and miR-21 targets Phosphatase and Tensin homolog (PTEN), a tumor suppressor, Programmed Cell Death protein 4 and B-cell lymphoma 2, a known cell death regulator [63, 64] . Both PTEN and Bcl-2 expression are dysregulated in endometriosis [65] [66] [67] [68] [69] . Furthermore, miR-21 upregulation inhibits RECK (also known as reversion-inducing-cysteine-rich protein with kazal motif), whose targets are MMPs-2 and -9 [70] . MMP-2 and -9 expression and enzyme activity are increased in women with endometriosis compared to controls [71, 72] . Therefore, we postulate that downregulation of miR-21 expression is potentially important in the pathobiology of endometriosis through regulation of PTEN and Bcl-2 expression as well as modulating expression of RECK and tissue remodeling enzymes MMP-2 and -9. (Figure 5 ). In the present study, miR-9 expression was significantly downregulated in women with PE compared to the eutopic endometrium of the same women only. There was no change in miR-9 expression found between ectopic lesion types or between eutopic endometrium of cases and controls. Our results contrast with the only one other study [25] that investigated miR-9 expression and its corresponding passenger strand (miR-9 * ). miR-9 expression was downregulated in women with endometriosis in the early secretory endometrium of women with (n = 4) and without (n = 3) endometriosis [25] . We speculate that the small number of participants precludes confidant analysis of menstrual cycle stage effects on differences in miRNA expression. In the present study, comparisons were made between ectopic lesions and eutopic endometrium collected from the same woman and thus differences are independent of menstrual cycle stage. We postulate that miR-9 contributes to the pathophysiology of endometriosis through regulation of cell death and cell proliferation. Pathway analysis confirmed that Bcl-2 mRNA was a miR-9 target [25] and consistent with the pro-survival phenotype observed in endometriotic cells ( Figure 5 ). Dysregulation of miR-9 is also associated with cell proliferation and inhibition of cell death in different cancers [24, 73] . In ovarian cancer, the suppression of miR-9 expression increased cell proliferation, cell growth, and anti-apoptotic properties in vitro [24] . We, and others, have previously shown that circulating concentrations of BDNF are elevated in women with endometriosis compared to control populations [52] [53] [54] . Prior studies in ovarian granulosa cells have shown that miR-10a, -10b, and -204 regulate BDNF expression [55] [56] [57] , and thus were selected for examination in the current study. Our results revealed that miR-10a is downregulated in the eutopic endometrium of women with DIE compared to controls, and in OMAs, it is downregulated in ectopic vs. eutopic tissue. Linear regression revealed a trend towards differential expression of miR-10a expression across lesion types (P = 0.049). miR-10b, which shares the same seed sequence as miR-10a and therefore shares the same group of targets, was downregulated in the eutopic endometrium of women with DIE compared to controls, and differentially expressed across lesion types, with a significant difference in OMAs and DIE. Finally, miR-204 is significantly downregulated in the eutopic endometrium of women with endometriosis compared to control endometrium. Specifically, miR-204 expression was significantly lower in the eutopic endometrium of women with OMAs and DIE compared to women from the control group. Taken together, these miRNAs are differentially regulated between controls and cases as well as within cases depending on the type of lesion present. Therefore, we propose that they play an important role in regulating BDNF expression and concentrations in women with endometriosis.
In a next-generation sequencing study [33] , miR-10a was downregulated in OMA compared to the endometrium of symptomatic controls. In human endometriotic cells, miR-10b has also been found to target and inversely regulate syndecan-1 (SDC-1) in endometriosis [74] . SDC1 is a transmembrane heparin sulfate proteoglycan that is involved in multiple disease pathways relevant to endometriosis. In human endometriotic cells, increased miR-10b resulted in decreased SDC-1 mediated cell invasiveness via downregulation of MMPs and protease inhibitor PAI-1, which are generally upregulated in endometriosis [74, 75] . Using an in silico approach, another group demonstrated that miR-10b negatively regulates the expression of BDNF by binding to its 3' UTR region [57] . Furthermore, miR-10b directly targets BDNF in goat granulosa cells, inhibiting cell proliferation [55] . Reintroduction of BDNF to the cells reversed the suppressive action of miR-10b, promoting cell growth and proliferation. While results of the present study suggest that miR-10a, -10b, and -204 are potentially important in the regulation of BDNF expression in endometriotic implants, we recognize that multiple miRNAs regulate BDNF expression. Accordingly, studies designed to quantify the expression of additional miRNAs known to regulate BDNF expression in other target tissues are ongoing. Furthermore, although beyond the scope of the present study, relationships between miRNA, BDNF gene, and protein expression in endometriotic implants remain to be elucidated.
Strengths of this study include the use of symptomatic controls with surgical exclusion of endometriosis. In addition, laparoscopy and histopathology was used to confirm endometriosis in women with chronic pelvic pain, while endometriosis was excluded in controls by laparoscopy providing confidence in assignment of participants to either case or control groups. Comparison of miRNA expression in different endometriotic lesion types was restricted to cases with exclusively one lesion type only to exclude potential influences of other lesion types on expression. Finally, since divergent results have been demonstrated depending upon the reference gene employed [28] , we used multiple reference genes that were stably expressed in all tissue samples to normalize miRNA expression. Furthermore, each of the control genes used were tested and stable expression across the samples used in this study was confirmed. Limitations with the current study include the lack of diversity in study subjects (predominantly Caucasian). Study participants were predominantly stage III-IV disease and thus the relevance of our findings for women with earlier stage disease (stages I-II) are unknown. Furthermore, the type of lesions collected (red, clear, blue-black, white, or chocolate cysts) was not consistently noted in surgical notes and recorded in our database and thus the effect of lesion activity on miRNA expression cannot be excluded. In addition, we cannot exclude the possibility that our tissue samples contain nonendometriotic cells and thus added another source of variation to our results. We suggest that use of laser capture microdissection would mitigate this issue in future studies. In view of the divergent results across studies, moving forward, it will be important to standardize definitions of case and controls, methods used, and the heterogeneity of this enigmatic disease. Finally, the effect of menstrual cycle stage on miRNA expression in the eutopic endometrium of women with endometriosis compared to a control population and in ectopic lesions has yet to be adequately addressed in the literature. Sample size limitations precluded the assessment of menstrual cycle stage effects in the present study, an issue that is the focus of ongoing investigations.
In summary, we have shown that miRNA expression differs between the eutopic endometrium of women with endometriosis compared to a symptomatic control population without endometriosis. Moreover, our results demonstrate that miRNA expression is dependent on the lesion type. Taken together, our data further support the proposal that different endometriotic lesions types are biochemically distinct. We suggest that identification of different miRNA expression patterns for OMA, PE, and DIE lesions could contribute to individualized patient care for women with endometriosis.
